OncoPharm podcast

Dostarlimab's Journey in MMRd Rectal Cancer

10/22/2026
0:00
10:59
Rewind 15 seconds
Fast Forward 15 seconds
This week we take a (brief) stop back in time to the beginning of dostarlimab's journey that has ended (for now) in an accelerated approval for rectal cancer that is mismatch repair-deficient or high in micro-satellite instability (MMRd/h-MSI). Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

More episodes from "OncoPharm"